When it comes to breast cancer, the first image people have is that this disease is associated with women, because breast cancer is one of the most common malignant tumors in women, accounting for 7-10% of all malignant tumors in China. In fact, breast cancer can also occur in men, and the incidence of male breast cancer accounts for 1% of female breast cancer, and the trend is increasing year by year. Since men also have a small amount of breast epithelial cells, it is possible for them to develop cancer due to the synergistic effect of hormones and various physical and chemical factors. It has been proven that high estrogen concentration stimulates the breast for a long time, which increases the risk of breast cancer in women. The low estrogen status in men is one of the most important reasons why the incidence of breast cancer in men is much lower than that in women. When estrogen levels increase in men, the risk of developing breast cancer increases. For men who have breast cancer in their family, liver inactivation due to liver cirrhosis, estrogen treatment for prostate cancer, testicular malformation, reduction of androgen secretion from the testes due to working in a hot environment, radiation therapy to the chest, male breast development, excessive obesity, and alcohol consumption can all increase the concentration of estrogen in the body, which may lead to the development of male breast cancer. Another risk factor for breast cancer is that men who work for more than 3 months in an environment where cyclic aromatic hydrocarbons such as gasoline and exhaust fumes cause cancer have a 2.5-fold increased risk of developing breast cancer. American scholars have also studied the effect of environmental factors on the incidence of breast cancer, pointing out that styrene, formaldehyde, methylene chloride, tetrachloromethane, trichloromethane, chromium, cobalt and copper are associated with the incidence of breast cancer, and pointing out that styrene is the environmental factor most closely related to the incidence of breast cancer. The first symptom of male breast cancer patients is usually a painless hard lump under the areola, and a mass in the outer upper quadrant of the breast is also more common. The lump is usually round or round-like with clear border and hard texture, and some patients may have nipple overflow. Because of the thinness of the male breast tissue and the lack of fat on the surface, the mass often involves the nipple or areola, causing eczema, indentation, recession, and ulceration of the nipple or areola. Since male nipple and areola are rich in lymphatic network, male breast cancer is prone to invade local lymph nodes, so the first symptom of some patients is enlarged axillary lymph nodes. Most male breast cancers can be diagnosed by triple methods, i.e. mammography, ultrasonography and pathological examination, the latter of which has two specific methods: cytological examination by fine needle aspiration and histological examination by puncture and excision. Radiography is an effective diagnostic technique for male breast cancer, and any male breast lump should be alerted for early diagnosis. The treatment of male breast cancer is mainly surgery, supplemented by chemotherapy, radiotherapy and endocrine therapy according to the condition. For male invasive breast cancer, axillary lymph node dissection should be performed. 2.Radiotherapy In the treatment of female breast cancer, it has been proved that adjuvant radiotherapy after radical breast cancer surgery can reduce the local recurrence rate up to 2/3 and improve the long-term survival rate. In addition, there are some factors that may affect recurrence, such as multiple lesions, poor pathological grading, high tumor proliferation rate, intravascular invasion around the tumor, and invasion of the mastectomy margin, etc. are also indications for radiotherapy. Systemic therapy is considered indispensable because estrogen receptor-positive male breast cancer accounts for more than 90% of the cases, and it is generally believed that triamcinolone acetonide can improve the incidence of estrogen receptor-positive female breast cancer. The use of triamcinolone is the standard approach to adjuvant hormone therapy for male breast cancer. Since men have fewer breast glands and are more prone to infiltration and metastasis, and men have a thinner subcutaneous fat layer, they tend to invade the subcutaneous lymphatic network earlier. Therefore, the prognosis of male breast cancer is generally considered to be worse than that of female breast cancer.